Stem Cell Therapy for Herniated Disc: Success Rate and What the Evidence Shows

Medically Reviewed by Dr. José A. Jiménez, Medical Director — Medical Doctor and Surgeon (UNAM), Specialist in Critical Care and Intensive Care Medicine, with advanced training in Stem Cell Therapy, Sports Medicine, and Musculoskeletal Ultrasound. More than 30 years of medical experience. Last Reviewed: August 2026

The published evidence on stem cell therapy for disc-related back pain is genuinely mixed, and we think you should know that before reading further.

A meta-analysis of nine studies covering 245 patients found statistically significant pain reduction and improved disability scores after mesenchymal stem cell treatment for intervertebral disc degeneration. A separate systematic review of intradiscal MSC therapy concluded there was insufficient evidence to support routine human use. Both are legitimate reviews of an evidence base that remains small and inconsistent.

There is no established success rate. What follows is what the studies show, where they disagree, and what that means if you are considering treatment.

Get an Appointment

Complete The Form Below And We’ll Get Back To You Immediately.

Herniated Disc or Degenerative Disc Disease?

These are related but distinct, and the distinction matters when reading research.

A herniated disc occurs when the soft inner material of a spinal disc pushes through its outer wall, often compressing a nearby nerve root. That compression is what produces radiating leg pain, numbness, or weakness.

Degenerative disc disease describes the gradual dehydration and thinning of discs over time, producing discogenic pain that is usually more localized to the back itself.

Most published stem cell research addresses disc degeneration and discogenic pain rather than acute herniation with nerve compression. This is important: if a herniated fragment is physically compressing a nerve, no injection removes that fragment. Regenerative therapy targets the inflammatory and degenerative environment around the disc, not the mechanical compression itself.

Any clinic that does not draw this distinction for you is not evaluating your case carefully.

Get an Appointment

Complete The Form Below And We’ll Get Back To You Immediately.

What the Published Research Shows

The supportive evidence. A systematic review and meta-analysis of nine clinical studies covering 245 patients with intervertebral disc degeneration found significantly reduced pain scores and improved Oswestry Disability Index results following MSC therapy, concluding the treatment may be effective for lumbar discogenic pain. The authors noted very high statistical heterogeneity between studies, meaning results varied considerably from trial to trial.

A meta-analysis of randomized controlled trials in Stem Cells International examined MSC transplantation for degenerative disc disease and similarly described it as a promising strategy, while noting that clinical evidence remained limited and contested.

The critical evidence. A more recent systematic review of intradiscal MSC therapy examined ten abstracts and eleven clinical studies, only one of which was a randomized controlled trial. Its conclusion was blunt: while animal model results are promising, the review found insufficient evidence to support the treatment’s use in humans, and called for further work on efficacy, safety, and patient selection.

How to hold both. These findings are not irreconcilable. They reflect a small evidence base with few randomized trials, variable protocols, and short follow-up. That is the honest state of the field in 2026 — promising enough to warrant serious study, not yet settled enough to promise outcomes.

What This Means If You Are Considering Treatment

A thin evidence base does not automatically mean a treatment will not help you. It means the decision needs to be made carefully, with realistic expectations, and with a clear understanding of the alternatives.

Several things follow from that. Be sceptical of any clinic quoting a specific success rate for disc treatment — the data does not support one. Ask whether your particular problem is degenerative or compressive, because they respond differently. Ask what happens if the treatment does not work, and confirm that surgical options remain available afterward.

And weigh it against what you would otherwise do. Spinal fusion and discectomy are effective procedures for the right patients, but they are irreversible and carry their own risks. For patients who are not yet surgical candidates, or who want to exhaust conservative options first, regenerative treatment for back pain occupies a reasonable place in that sequence.

Recovery Time and What to Expect

The procedure itself is minimally invasive and performed on an outpatient basis. Most patients resume light activity within a few days, in contrast to spinal surgery, which typically involves weeks of restricted activity and a structured rehabilitation programme.

Improvement, where it occurs, tends to be gradual rather than immediate. Studies reporting outcomes generally measure at three, six, and twelve months, with changes developing over weeks to months rather than days. Patients expecting immediate relief are frequently disappointed even when the treatment eventually helps.

Reported adverse events across the published studies have been limited, most commonly temporary soreness or increased discomfort in the days following the procedure.

Illustration of stem cells in a scientific setting, representing regenerative medicine for herniated disc treatment.

Who Is and Is Not a Candidate

Patients with discogenic pain from disc degeneration, without severe nerve compression, tend to be the more appropriate candidates. Patients who have failed conservative management but are not yet ready for surgery are also frequently evaluated.

Regenerative treatment is less appropriate where there is significant nerve compression producing progressive neurological deficit, where there is spinal instability, or where cauda equina symptoms are present. These require urgent surgical assessment, not an injection, and we will refer rather than treat.

Stem cell therapy is also generally not appropriate during active malignancy, active systemic infection, pregnancy, or with certain blood disorders.

Recent MRI imaging is essential to this evaluation. Without it, no one can responsibly tell you whether your back pain is a candidate for regenerative treatment.

How Renovo Clinic Evaluates Disc Patients

Our process begins with a comprehensive evaluation covering your history, symptom pattern, prior treatments, and imaging. Dr. José A. Jiménez brings more than 30 years of medical experience, including advanced training in musculoskeletal ultrasound, to that assessment.

From there we develop a personalized plan. Stem cell therapy for the spine is not a single fixed procedure — the approach depends on whether your pain is discogenic or compressive, which levels are involved, the delivery route, and whether treatment is staged across more than one session. Those decisions follow from your imaging, not from a standard package.

For a meaningful minority of patients, the right recommendation is that stem cell therapy is not appropriate and a surgical referral is. We make it.

We maintain follow-up after treatment and adjust the plan as your response becomes clear, rather than treating the procedure as the end of the process.

Renovo Clinic is located at the Plaza Toreo City Complex in Tijuana, approximately 8 minutes from the U.S. border. Patients travelling from the United States should bring recent imaging so the evaluation can be completed in a single visit. Contact us to arrange a consultation.

Frequently Asked Questions

No established success rate exists. A meta-analysis of 245 patients found significant pain and disability improvements after MSC therapy for disc degeneration, while a separate systematic review found insufficient evidence to support human use. The evidence base is small and inconsistent, and any specific percentage should be treated with caution.

For discogenic pain arising from disc degeneration, some studies report meaningful improvement in pain and function. For back pain caused by mechanical nerve compression from a herniated fragment, regenerative therapy does not remove the compression and is less likely to resolve the problem.

Stem cell therapy does not physically retract herniated material. It targets the inflammatory and degenerative environment in and around the disc. Claims that an injection will repair a herniation outright are not supported by current evidence.

The procedure is outpatient and minimally invasive, with most patients resuming light activity within days. Improvement, where it occurs, develops gradually over weeks to months rather than immediately.

They suit different situations. Surgery is effective and sometimes necessary, particularly where there is progressive neurological deficit or instability. Regenerative treatment is an option earlier in the sequence, and it does not remove surgery as a later possibility.

Yes. Recent imaging is essential to determine whether your pain is degenerative or compressive, which determines whether regenerative treatment is appropriate at all.

Reported adverse events in published studies have been limited, most commonly temporary soreness or increased discomfort following the procedure. All medical procedures carry risk, and these are discussed during evaluation.

Recent Posts